

## SARC Semiannual Meeting Agenda

Friday, June 4, 2021

9:00 am – 12:00 pm EDT

<b>9:00</b>	<b>Chawla-Rosenfeld Developmental Therapeutics Symposium</b>	
	<b>Introduction</b>	<b>Jonathan Fletcher, MD</b> (Harvard Medical School)
	<b>Overview of Radiomics Accomplishments</b>	<b>Amber Simpson, PhD</b> (Queens University, Ontario)
	<b>Radiomics-based Patient inclusion model improves clinical trial performance</b>	<b>Robert Gillies, PhD</b> (Moffitt Cancer Center)
	<b>Future Directions and Opportunities</b>	<b>Benjamin Haibe-Kains, PhD</b> (University of Toronto)
	<b>Discussion/Q&amp;A</b>	<b>Speakers &amp; Co-Moderators:</b> <b>Amandine Crombe, MD</b> (Institut Bergonié) <b>William Tap, MD</b> (Memorial Sloan Kettering Cancer Center)
<b>10:30</b>	<b>SARC Clinical Trials: Open/Opening</b>	
	<b>Principal Investigators</b>	
	<b>Introductions: SARC Medical Officer</b>	<b>Scott Okuno, MD</b>
	<b>SARC024:</b> Phase 2 oral regorafenib in patients with selected sarcoma subtypes	<b>Robert Maki, MD, PhD</b> Steven Attia, DO Leo Mascarenhas, MD Richard Riedel, MD Christopher Ryan, MD
	<b>SARC031:</b> Phase 2 MEK inhibitor selumetinib w/ dual mTOR kinase inhibitor sirolimus in MPNST	<b>AeRang Kim, MD, PhD</b> Brigitte Widemann, MD
	<b>SARC032:</b> Phase 2 Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Soft Tissue Sarcoma of the Extremity	<b>David Kirsch, MD, PhD</b> Brian Brigman, MD, PhD Yvonne Mowery, MD, PhD Richard Riedel, MD
	<b>SARC037:</b> Phase I Trabectedin in Ewing Sarcoma in Combination with Irinotecan and 18F-FLT Imaging	<b>Patrick Grohar, MD, PhD</b>
	<b>SARC038:</b> Phase 2 Regorafenib in Combination with Nivolumab in Osteosarcoma	<b>Fariba Navid, MD</b> Lara Davis, MD
	<b>SARC041:</b> Phase 3 Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS	<b>Mark Dickson, MD</b>
	<b>Q&amp;A</b>	<b>Speakers &amp; Medical Officer</b>
<b>11:00</b>	<b>Sarcoma Advocacy</b>	
	<b>FDA Patient Advocacy Engagement</b>	<b>Leslie Doros, MD</b> (Medical Officer, U.S. Food and Drug Administration)
	<b>Sarcoma Coalition</b>	<b>Lynne Hernandez</b> (Desmoid Tumor Research Foundation)
	<b>SARC Sarcoma Research Advocacy Council</b>	<b>Peter Fantozzi</b> (Northwest Sarcoma Foundation)
<b>11:30</b>	<b>SARC Strategic Opportunities</b>	
	<b>The Future of SARC</b>	<b>Chappie Conrad, MD</b> (Chair, Board of Directors)
	<b>Maximizing Impact: Strategies &amp; Resources</b>	<b>Steven Young</b> (President & CEO)
	<b>Scientific Challenges &amp; Opportunities</b>	<b>Jonathan Fletcher, MD</b>
	<b>Q&amp;A</b>	<b>Speakers</b>
<b>12:00</b>	<b>Adjourn</b>	